Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Common Equity (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Common Equity for 10 consecutive years, with -$80.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 131.37% to -$80.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$80.0 million through Dec 2025, down 131.37% year-over-year, with the annual reading at -$80.0 million for FY2025, 131.37% down from the prior year.
  • Common Equity for Q4 2025 was -$80.0 million at Ultragenyx Pharmaceutical, down from $9.2 million in the prior quarter.
  • The five-year high for Common Equity was $1.1 billion in Q1 2021, with the low at -$80.0 million in Q4 2025.
  • Average Common Equity over 5 years is $411.7 million, with a median of $310.9 million recorded in 2023.
  • The sharpest move saw Common Equity surged 993.61% in 2024, then plummeted 131.37% in 2025.
  • Over 5 years, Common Equity stood at $922.6 million in 2021, then tumbled by 61.85% to $352.0 million in 2022, then dropped by 21.88% to $275.0 million in 2023, then fell by 7.27% to $255.0 million in 2024, then plummeted by 131.37% to -$80.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$80.0 million, $9.2 million, and $151.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.